Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial

M. Kolb (Hamilton, Ontario, Canada), A. Wells (London, United Kingdom), J. Behr (Munich, Germany), L. Richeldi (Rome, Italy), B. Schinzel (Heidelberg, Germany), M. Quaresma (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany), G. Raghu (Seattle, Washington, United States of America), F. Martinez (New York, New York, United States of America)

Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias
Session: Clinical news in idiopathic interstitial pneumonias
Session type: Oral Presentation
Number: 546
Disease area: Interstitial lung diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Kolb (Hamilton, Ontario, Canada), A. Wells (London, United Kingdom), J. Behr (Munich, Germany), L. Richeldi (Rome, Italy), B. Schinzel (Heidelberg, Germany), M. Quaresma (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany), G. Raghu (Seattle, Washington, United States of America), F. Martinez (New York, New York, United States of America). Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial. 546

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: